FDA approves ready-to-use norepinephrine injections for severe hypotension
Baxter International has received FDA approval for its premixed doses of Norepinephrine Bitartrate in 5% Dextrose Injection, a ready-to-use treatment for patients with severe, acute hypotension.
According to Baxter, this is the one available norepinephrine treatment that does not have to be manually compounded to fill each individual prescription, making it much more convenient for healthcare providers.
“In a critical care situation, speed, efficiency and safety are of the utmost priority,” Heather Knight, Baxter’s general manager of U.S. hospital products, said in a prepared statement. “Our ready-to-use formulation of norepinephrine allows hospitals to store this medication closer to patient care settings like the emergency department, intensive care unit and surgical areas, letting them administer it faster while reducing the risk of compounding errors or touch contamination.”
The injections are available at 4 mg and 8 mg strengths, and can be stored at room temperature for up to 90 days. When properly refrigerated, the treatments were designed to last for up to 21 months.
Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.